Prospective Interns
Previous Opportunities
Abstracts from previous internship opportunities will be posted here.
- 2012 Project A: Assessment of functional impact score of somatic mutations for outcome prediction in TCGA datasets (GBM, Ovarian and Colorectal)
Supervisor: Dr. Paul C. Boutros, Principal Investigator at Informatics & Biocomputing Ontario Institute for Cancer Research Collaborators: Multiple collaborators Location: Ontario Institute for Cancer Research, Toronto Research Plan: Glioblastoma multiforme (GBM), Ovarian and Colorectal cancers are amongst the most malignant cancers types. In 2010, an estimated 22,000, 21,888 and 142,270 patients were diagnosed with GBM, [...]
- 2012 Project B: Statistical Models to Assess the Clinical Importance of Rare Genetic Variants in Cancer
Supervisor: Dr. Paul C. Boutros, Principal Investigator at Informatics & Biocomputing, Ontario Institute for Cancer Research Collaborators: Dr. Ben Neel, Professor at Department of Medical Biophysics, University of Toronto, and Senior Scientist at Ontario Cancer Institute Dr. Bradly Wouters, Professor at Department of Medical Biophysics, University of Toronto, and Senior Scientist at Ontario Cancer Institute [...]
- 2012 Project C: Meta-Analysis of Prostate Cancer Genomic Datasets
Supervisor: Dr. Paul C. Boutros, Principal Investigator at Informatics & Biocomputing, Ontario Institute for Cancer Research Collaborators: Dr. Robert Bristow, Professor at Department of Radiation Oncology, University of Toronto, Staff Radiation Oncologist at Princess Margaret Hospital/University Health Network, Senior Scientist at Ontario Cancer Institute Dr. Theo can der Kwast, Department of Laboratory Medicine and Pathology, [...]
- 2012 Project D: Integrated Prognostic mRNA and miRNA Signatures for Cervix Cancer Outcome
Supervisor: Dr. Paul C. Boutros, Principal Investigator at Informatics & Biocomputing, Ontario Institute for Cancer Research Collaborator: Dr. Fei-Fei Liu, Professor at Department of Radiation Oncology, University of Toronto, Staff Radiation Oncologist at Princess Margaret Hospital/University Health Network, Senior Scientist at Ontario Cancer Institute Location: Ontario Institute for Cancer Research, Toronto Research Plan: Cervix cancer [...]
- 2012 Project E: Methodological Approaches for an Integrated Translational Pharmacogenomic Research in Esophageal Cancer: From Pre-Clinical Mouse Models to Genome Wide Association Studies and Combined Biostatistical-Bioinformatic Approaches
Supervisors: Dr. Wei Xu, Senior Biostatistician at Princess Margaret Hospital, Scientist at Ontario Cancer Institute, and Assistant Professor of Biostatistics in School of Public Health at University of Toronto Dr. Geoffrey Liu, Medical Oncologist at Princess Margaret Hospital, Pharmacogenetic Epidemiologist, Scientist at Ontario Cancer Institute, and Visiting Scientist at Harvard School of Public Health Location: [...]
- 2012 Project F: Genetic polymorphisms and head and neck cancer outcomesin PMH/OCI
Supervisors: Dr. Wei Xu, Senior Biostatistician at Princess Margaret Hospital, Scientist at Ontario Cancer Institute, and Assistant Professor of Biostatistics in School of Public Health at University of Toronto Dr. Geoffrey Liu, Medical Oncologist at Princess Margaret Hospital, Pharmacogenetic Epidemiologist, Scientist at Ontario Cancer Institute, and Visiting Scientist at Harvard School of Public Health Daryl [...]
- 2012 Project G: Multi-Marker Model in Cancer Clinical Trials
Supervisor: Dr. Keyue Ding, Senior Biostatisticians at NCIC Clinical Trials Group Location: Kingston, Ontario Research Plan: High-throughput assays have allowed researcher to discover novel biomarkers and differentially expressed genes. And various statistical issues for analyzing such data being raised, and different modelling techniques have been proposed to deal with issues. This project is to explore [...]
- 2011 Integrated Prognostic mRNA and miRNA Signatures for Cervix Cancer Outcome
Supervisor: Dr. Paul C. Boutros Location: Ontario Institute for Cancer Research, Toronto Cervix cancer is the second most common malignancy in women worldwide, yet to date there are no validated prognostic biomarkers in clinical use. In fact, very few such studies have yet been performed. To fill this gap, we comprehensively profiled miRNA and mRNA [...]
- 2011 Statistical Models to Assess the Clinical Importance of Rare Genetic Variants in Cancer
Supervisor: Dr. Paul Boutros Location: Ontario Institute for Cancer Research, Toronto Current cancer drug development typically targets oncogenes and their signalling pathways, based on the premise that tumours become “addicted” to these genes/pathways. Due to these mutations, tumours can also become unusually dependent on pathways that are not directly affected by mutation; we refer to [...]
- 2011 Meta-Analysis of Prostate Cancer Genomic Datasets
Supervisor: Dr. Paul Boutros Location: Ontario Institute for Cancer Research, Toronto Prostate cancer (CaP) is the most commonly diagnosed malignancy in Canadian men. In 2011, it is predicted that almost 25,000 men will be diagnosed with CaP, and more than 4,000 are expected to die from the disease. It is now the third most common [...]
- 2011 Finding Biomedical Markers in Lung and Cervix Cancer
Supervisor: Melania Pintilie Location: Princess Margaret Hospital, Toronto PMH/OCI has a leading role in cancer research with more than $100 million in external grant funding for the year of 2010. In the medical research world a large effort is directed towards personalized medicine and translational research. During this process, of great importance is the finding [...]
- 2011 Methodological Biostatistical Approaches for Clinical Oncology Research
Supervisor: Wei Xu Co-supervisors: Geoffrey Liu Location: Princess Margaret Hospital Proposed Study A: Genetic polymorphisms and head and neck cancer outcomes The objective of this study is to evaluate molecular prognostic markers in head and neck cancer (HNC) outcomes (1), as clinical prognostic factors are imprecise, and improving our ability to predict clinical outcomes is [...]
- 2011 Effect of Dependent Censoring on Body Mass Index (BMI) and Clinical Outcome in Highly Censored Early Breast Cancer
Supervisor: Judy-Anne Chapman Co-supervisors: Bin Dong Location: NCIC Clinical Trials Group, Queen’s University Pooling of NCIC Clinical Trials Group breast cancer trials recently led to the unexpected consistent result that increases in BMI from baseline were associated with improved relapse-free survival, although higher baseline BMI had the expected shortening of relapse-free period. Assessment of BMI [...]
- 2011 The Prostate Cancer Risk Stratification (ProCaRS) Project
Supervisor: Dr. George Rodrigues Co-supervisors: Drs. Himu Lukka (Hamilton), Padraig Warde (PMH), Tom Pickles (BC), Juanita Crook (BC), Michael Brundage (Kingston), Luis Souhami (McGill) Location: London Regional Cancer Program The Genitourinary Radiation Oncologists of Canada (GUROC) have previously published a consensus statement on the management of prostate cancer in 2001. This consensus statement included details [...]
- 2011 Pharmacogenetic Analysis of NCIC Clinical Trials Group BR.24 Study: Genome Wide Association Study (GWAS), post GWAS, and Pathway Analyses: A Combined Queens-OCI-OICR Collaboration
Supervisors: Bingshu Chen, Geoffrey Liu, Paul Boutros Location: Toronto and Kingston NCIC CTG BR.24 is a randomized clinical trial of chemotherapy with or without a molecularly targeted drug against the VEGF pathway. Unexpected toxicities led to this study terminating early. This increase in toxicities has led to a testable hypothesis that genetic factors may have [...]
- 2011 Genetic polymorphisms and head and neck cancer outcomes
Supervisor: Wei Xu, Senior Biostatistician, Department of Biostatistics, Princess Margaret Hospital and Assistant Professor of Biostatistics, School of Public Health, University of Toronto Research Plan: The objective of this study is to evaluate molecular prognostic markers in head and neck cancer (HNC) outcomes (15), as clinical prognostic factors are imprecise, and improving our ability to [...]
- 2011 MRS/US Prostate Cancer Biopsy Data Analysis
Supervisors: Wenqing He, Statistical and Actuarial Sciences, University of Western Ontario Collaborators: Aaron Fenster (Canada Research Chair, Chair, Division of Imaging Sciences, Department of Medical Imaging, Program Leader OICR Imaging Program Platform), Joseph Chin (Professor and Head, Division of Surgical Oncology, Department of Oncology, member OICR Imaging Program Platform), Glenn Bauman (Professor and Chair, Department [...]
- 2011 Biomarker Signature Detection in NCIC BR10 Lung Cancer Trial
Supervisors: Melania Pintile MSc, Statistician, Ontario Cancer Institute/Princess Margaret Hospital Collaborators: Frances Shepherd (Professor of Medicine, University of Toronto and Chair, Lung Cancer Site Committee of NCIC-CTG Lung), Ming Tsao (Director of the Lung Cancer Translational Research Laboratory, Princess Margaret Hospital) Research Plan: A major goal in translational cancer research is to identify biomarkers which [...]
- 2011 Joint Models for longitudinal data and time to event data with application to quality of life analysis in NCIC CTG myeloma trials
Supervisors: Bingshu Chen and Keyue Ding, Senior Biostatisticians, NCIC Clinical Trials Group Research Plan: Quality of Life (QoL) outcomes represent a very important response in cancer clinical trials, which can play a large role in both efficacy and safety analysis of new therapeutic agents (1). Missing data in quality of life assessments may not be [...]
